CSL Limited (ASX:CSL): What Do FY26 Impairments and Plasma Operations Reveal?

Aditi Sarkar

12 November 2026 04:39 PM AEDT

CSL Limited (ASX:CSL): What Do FY26 Impairments and Plasma Operations Reveal?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

CSL (ASX:CSL) reported FY26 total Operating Revenue of US$15.8 billion.
Underlying NPATA attributable to shareholders was approximately US$3.1 billion.
Restructuring and impairments contributed to a reported Shareholder loss of US$2.6 billion.
Operating cash flow reached approximately US$3.5 billion during FY26.

CSL Limited (ASX:CSL) develops and supplies plasma-derived therapies, influenza vaccines and treatments for specialised medical conditions through its international biopharmaceutical businesses. On 12 November 2026, CSL shares were quoted at AUD 203.84, up 1.07% during the session. Its 2026 financial reporting brought attention to the difference between underlying operating Earnings and the reported loss associated with restructuring and Impairment charges. The company also outlined priorities for its plasma medicines, vaccines and iron therapies operations.

Plasma, Vaccines and Specialised Medicines

CSL (ASX:CSL) operates through CSL Behring, CSL Seqirus and CSL Vifor. Behring develops and markets therapies for immunodeficiency, bleeding disorders and other serious conditions, drawing on plasma collection and specialist manufacturing. Seqirus supplies influenza vaccines, while Vifor covers medicines including products addressing iron deficiency. The businesses serve markets worldwide, with manufacturing, research and commercial activities spread across several regions. Their Demand profiles differ: plasma therapy relies on collection and fractionation capacity; vaccines involve seasonal procurement and production; and iron products face competitive and regulatory dynamics. These differences are relevant when comparing divisional performance.

FY26 Results and the Reported Loss

In August 2026, CSL (ASX:CSL) released results for the year ended 30 June 2026. Total operating revenue was US$15.797 billion, while underlying NPATA attributable to CSL shareholders was US$3.098 billion. The company separately recorded a net loss attributable to shareholders of US$2.579 billion. Its statutory figures included restructuring and impairment expenses of US$7.923 billion before tax, creating a substantial distinction between underlying and reported measures. Underlying results exclude specified significant items; they do not remove the economic relevance of any impairment or restructuring programme. Readers assessing profitability should therefore consider both measures and the associated accounting explanations.

Segment Performance, Cash Flow and Outlook

The FY26 Annual Report recorded revenue of US$11.387 billion in Behring, US$2.031 billion in Seqirus and US$2.379 billion in Vifor. Cash flow from Operating Activities was about US$3.512 billion, providing a separate view of cash generation alongside accounting losses. CSL (ASX:CSL) maintained total FY26 dividends of US$2.92 a share. Its stated FY27 outlook anticipated mid-single-digit constant-currency revenue growth for Behring and low-single-digit revenue growth for Seqirus, while Vifor faced generic competition and the effects of a product Withdrawal in European markets. These are management expectations, rather than completed outcomes.

Risks and Execution Considerations

CSL (ASX:CSL) remains exposed to plasma collection economics, Manufacturing reliability, product safety obligations and regulatory scrutiny. Vaccination programmes are sensitive to procurement decisions, public-health demand and the timing of influenza seasons. Competition from generic products can affect pricing and volumes in parts of Vifor’s portfolio. The transformation programme adds execution considerations, including costs, timing and the extent to which operational changes affect reported future results. Differences between constant-currency and reported revenue also matter for a company operating across multiple currencies.

What to Watch Next

Subsequent disclosures can show whether plasma demand, collection efficiencies and the Behring revenue trajectory align with management’s FY27 expectations. Investors can also monitor the Seqirus seasonal programme, Vifor’s product mix, restructuring expenses and the conversion of underlying profits into operating cash flow. CSL (ASX:CSL) has scheduled its FY27 half-year results for February 2027. Any reassessment of asset values or transformation costs would need to be evaluated alongside the statutory accounts, rather than only the Underlying Profit measure.

Key Insights

CSL (ASX:CSL) entered the new financial year with diverse biopharmaceutical operations, operating cash inflows and significant FY26 impairment-related charges. The central distinction is between underlying trading measures and the statutory loss. Segment growth, commercial execution and the financial effects of restructuring are the main elements to monitor in subsequent company reporting.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.